CompletedPhase 1NCT02874989

Targeting Pro-Inflammatory Cells in Idiopathic Pulmonary Fibrosis: a Human Trial

Studying Idiopathic pulmonary fibrosis

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Wake Forest University Health Sciences
Principal Investigator
Stephen Kritchevsky, PhD
Wake Forest Univerisity Health Sciences
Intervention
Dasatinib + Quercetin(drug)
Enrollment
26 enrolled
Eligibility
50 years · All sexes
Timeline
2016 – 2019

Study locations (2)

Collaborators

Mayo Clinic · The University of Texas Health Science Center at San Antonio

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02874989 on ClinicalTrials.gov

Other trials for Idiopathic pulmonary fibrosis

Additional recruiting or active studies for the same condition.

See all trials for Idiopathic pulmonary fibrosis →

← Back to all trials